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AIDS vaccines associated with the puriﬁcation of HIV envelope, we developed a new
puriﬁcation method exploiting the high afﬁnity of a peptide mimicking CD4 towards the viral glycoprotein.
This miniCD4 was used as a ligand in afﬁnity chromatography and allowed the separation in one step of HIV
envelope monomer from cell supernatant and the capture of pre-puriﬁed trimer. This simple and robust
method of puriﬁcation yielded to active and intact HIV envelopes as proved by the binding of CCR5 HIV co-
receptor, CD4 and a panel of well-characterized monoclonal antibodies. The immunogenicity of miniCD4-
puriﬁed HIV envelope was further assessed in rats. The analysis of the humoral response indicated that
elicited antibodies were able to recognize a broad range of HIV envelopes. Finally, this method based on a
chemically synthesized peptide may represent a convenient and versatile tool for protein puriﬁcation
compatible far scale-up in both academic and pharmaceutical researches.
© 2008 Elsevier Inc. All rights reserved.IntroductionAcquired immunodeﬁciency syndrome (AIDS) continues to be a
major health problem throughout the world. In 2007 approximately
33 million people infected with the human immunodeﬁciency virus
type 1 (HIV-1), 2.5 million new infections, and 2.1 million people died
of AIDS-related illnesses (UNAIDS/WHO, 2007). Therefore, there is an
urgent need for an effective anti-HIV vaccine. The HIV-1 envelope
glycoprotein (Env) is the target of broadly neutralizing antibodies and
should be an important component of a successful HIV vaccine (Girard
et al., 2006; Phogat and Wyatt, 2007). Env is formed by gp120 and
gp41 that result from the cleavage of gp160 precursor (McCune et al.,
1988). These two subunits are noncovalently associated in a trimeric
structure (Wyatt and Sodroski, 1998). In order to mimic the native
form of HIV-1 envelope, gp140 non-covalent trimer lacking gp41
trans-membrane domain has been engineered (Jeffs et al., 2004; Kieny
et al., 1988; Sanders et al., 2002; Srivastava et al., 2002, 2003).
RecombinantHIV-1 glycoproteins are produced at high scale in both
trimeric and monomeric forms for pre-clinical and clinical researches
on HIV vaccine. Several studies have demonstrated that gp140 is
particularly attractive as potent immunogen and that oligomers are
more effective in inducing strong antibody responses to conformational
epitopes compared to monomer (Barnett et al., 2008; Mascola et al.,l rights reserved.1996; Srivastava et al., 2003; Zhang et al., 2007). Indeed, the few
monoclonal antibodies (mAbs) that potently neutralize HIV-1 all
recognize epitopes exposed on the native Env complex (Burton and
Parren, 2000, Fouts et al.,1998; Parren et al.,1998; Sattentau andMoore,
1995). In contrast, non-neutralizingmAbs that do not bind to the native
complex have been found following vaccination with gp120 monomer
(Burton and Parren, 2000, Parren et al., 1998). Therefore it is important
to produce Env oligomers with intact epitopes and functional receptor
binding sites for inclusion in a potential HIV-vaccine.
In order to address this point, we have developed a newmethod of
puriﬁcation of HIV-1 Env suitable for the capture of gp120 or gp140.
There are few pre-existing methods for the puriﬁcation and the
preparation of active Env. Two main approaches can be pinpointed.
First, lectin is utilized in afﬁnity chromatography to capture
glycoproteins (Cefai et al., 1990; Jeffs et al., 2004; Jones et al., 1995,
Srivastava et al., 2002, 2003). Unfortunately, this approach is
unspeciﬁc to HIV-1 Env and requires several additional steps of
puriﬁcation such as ion exchange and size exclusion chromatography.
Second, Env glycoproteins are puriﬁed with anti-gp120 or anti-gp140
mAbs (Jeffs et al., 2004; Kalyanaraman et al., 1990; Kwong et al., 1999).
This approach presents several difﬁculties. Antibody-based methods
are expensive and necessitate the coupling of anti-Env antibody to a
solid support, which may reduce its afﬁnity for Env. Moreover, there
are few antibodies suitable for the puriﬁcation of a large panel of
envelope; and the half-life of antibody is relatively limited, particu-
larly when used in acidic conditions.
Table 1
Yield of puriﬁcation of miniCD4 afﬁnity chromatography
Step Volume (ml) gp120SF162 (μg) % of recovery Purity (%)
Culture supernatant 0.5 72.2±12.5
MiniCD4 eluate 1.5 40.3±4.12 55.8 60
Number of independent experiments: n=9.
Fig. 2. Binding of miniCD4-puriﬁed gp120SF162 to CCR5 chemokine receptor. Over-
expressing CCR5 cells were incubatedwith 100 ng of gp120SF162without (lanes 1 and 2)
or with 36 ng of sCD4 (lanes 3 and 4). Bound envelope glycoprotein was detected with
D7324 anti-gp120 mAb. Cells were analyzed for envelope binding by FACS ﬂow
cytometry. Lane 1—miniCD4-puriﬁed gp120SF162; lane 2—gp120SF162 puriﬁed by the
reference method; lane 3—miniCD4-puriﬁed gp120SF162+ sCD4; lane 4—gp120SF162
puriﬁed by the reference method+sCD4.
242 G. Martin et al. / Virology 381 (2008) 241–250Our objective was to deﬁne a new method of puriﬁcation of HIV
envelope, which was simple, robust, not expensive, suitable for
envelope monomer or trimer and above all, which preserved HIV
envelope antigenicity and its ability to bind both CD4 and chemokine
receptor. Therefore, we investigated the usefulness of a peptide
mimicking the human receptor CD4 as a ligand in afﬁnity chromato-
graphy. MiniCD4 peptides were initially obtained by the transfer of
critical elements of CD4/gp120 interface onto a structurally compa-
tible small scaffold (Martin et al., 2003; Vita et al., 1999). Their afﬁnity
towards gp120 and gp140 had been improved by combinatorial
chemistry and directed amino-acid substitution based on the crystal
structure of the complex gp120-miniCD4 (Huang et al., 2005; Stricher
et al., 2005, 2008; Van Herrewege et al., 2008). In the afﬁnity
chromatography method presented here, we used CD4M48 an
optimized version of miniCD4 that presents a sub-nanomolar afﬁnity
for SF162 isolate and a CD4-like afﬁnity for clade B envelopes in
neutralization assays (Stricher et al., 2008; Van Herrewege et al.,
2008). The miniCD4 was grafted to a solid support and evaluated for
its ability to purify gp120SF162 and gp120YU2 from mammalian cell
supernatant. In parallel, the peptide was assessed for its capacity to
capture gp140SF162 trimer. The yield of puriﬁcation of each HIV-1 Env
was measured and antigenic properties of miniCD4-puriﬁed Env were
evaluated through the binding of CD4, CCR5 co-receptor and a panel of
well-characterized neutralizing monoclonal antibodies. Finally, the
immunogenicity of miniCD4-puriﬁed gp120YU2 was evaluated in a
small scale animal trial.
Results
Puriﬁcation of monomeric HIV envelope by miniCD4
A miniCD4-based afﬁnity chromatography was designed to purify
monomeric HIV-1 envelope from supernatant of cell over-expressingFig. 1. Puriﬁcation of gp120SF162 by the miniCD4 method. Analysis of miniCD4-puriﬁed g
miniCD4 beads incubation; lane 2—pool of miniCD4 elutions. Lane 3 immunoblot: identiﬁcat
HPLC proﬁle of miniCD4-puriﬁed gp120SF162 (B). Fractions composing peak C were pooledgp120SF162. 500 μl of cell supernatant (approximate concentration of
gp120SF162: 150 mg/L) was incubated with 500 μl of miniCD4-beads.
Bound proteins were then eluted in 1.5 ml of citric acid instanta-
neously neutralized by citrate buffer (see materials and methods).
The yield of miniCD4-afﬁnity chromatography was evaluated by a
CD4 binding assay through the measurement of the concentration of
active gp120SF162 in cell supernatant and in the three fractions eluted
from miniCD4-beads (Table 1). Typically, cell supernatant or eluted
fractions (named E1–E3) were incubated in the presence of immobi-
lized D7324 anti-gp120mAb. Bound proteins were then detected after
three subsequent incubations with (i) soluble CD4 (sCD4), (ii) L120.3
anti-CD4 mAb, (iii) a HRP labeled antibody directed against L120.3
mAb. Concentrations of gp120SF162 before and after miniCD4 capture
were evaluated by comparison to several dilutions of gp120SF162 at
known concentrations (gp120SF162 puriﬁed with the multi-step
method). In the whole study, the multi-step method of puriﬁcation
of HIV envelope was used as a method of reference (see materials andp120SF162 by SDS-PAGE (A). Lanes l and 2 silver staining: lane 1—ﬂowthrough after
ion of gp120SF162 among the eluted protein by anti-gp120 D7324 mAb. Size exclusion-
and analyzed by SDS-PAGE followed by a silver staining (C).
Fig. 3. Binding sensorgrams of miniCD4-puriﬁed gp120SF162 to anti-gp120 mAbs. The
binding of miniCD4-puriﬁed gp120SF162 on 48D (A) or X5 (B) antibody, in the presence
or not of 100 nM sCD4 (soluble CD4) was analyzed by surface plasmon resonance (SPR).
Binding sensorgrams of miniCD4-puriﬁed gp120SF162 diluted at 50 nM, 25 nM,
12.5 nM, 6.25 nM and 3.125 nM to b12 (C) or 447-52D (D) mAbs.
Fig. 4. Comparison of the binding to a panel of well-characterized mAbs of miniCD4-puriﬁed g
miniCD4-puriﬁedgp120SF162 (open square) andgp120SF162 puriﬁedwith amulti-stepmethod
concentration of soluble CD4 (addition of sCD4 for panels D, E and F) on immobilized lectin (Con
(E); 17b (F); 447-52D (G); 2G12 (H). Anti-gp120 mAbs binding was ﬁnally detected with peroxi
signal of 4 independent experiments. Legends: “multi”: gp120SF162 puriﬁed with the multi-ste
243G. Martin et al. / Virology 381 (2008) 241–250methods). This method involving a capture and two cleaning steps
had been shown to efﬁciently purify either HIV envelope monomer or
trimer (Srivastava et al., 2002, 2003). We carried out 9 independent
experiments and obtained 55.8% as average yield of puriﬁcation with
the miniCD4 afﬁnity chromatography method.
At the same time, captured proteins were analyzed by SDS-PAGE,
immunoblot, and size exclusion chromatography (SEC) (Fig. 1).
Puriﬁcation of gp120SF162 was achieved with a degree of purity of
approximately 60% as shown by SDS-PAGE followed by silver staining
(Fig. 1A, lane 2). The major contaminant was shown to be a serum
protein, identiﬁed by N-terminal sequencing as bovine serum albumin
precursor (Fig. 1A, lane 2). The identity of HIV envelopewas conﬁrmed
by immunoblot using anti-gp120 D7324 mAb (Fig. 1A, lane 3).
MiniCD4-puriﬁed gp120SF162 was further analyzed on a pre-
calibrated Bio-Sil 250 column (Fig. 1B). Consistent with SDS-PAGE
analysis, the elution proﬁle shows that only a low amount of aggregate
was eluted in death volume and peak A fractions. The elution volume
of peak C fractions corresponds to protein with gp120 molecular
weight (7.4 ml). Peak B fractions could be composed of gp120
aggregates or by non-envelope proteins found in cell supernatant,p120SF162 and gp120SF162 puriﬁed with a multi-step method. Various concentrations of
(referencemethod,ﬁlled square)were pre-incubated in thepresenceor not of an equimolar
canavalin A) and incubatedwith severalmAbs i.e. D7324 (A); b12 (B); F105 (C); 48D (D); X5
dase-labeled secondary antibodies. This ﬁgure shows the representative antibody-binding
p procedure, “miniCD4”: gp120SF162 puriﬁed by miniCD4 afﬁnity chromatography.
Fig. 5. Puriﬁcation of gp140SF162ΔV2 by the miniCD4 method. SF162 envelope trimer puriﬁed by the multi-step method was applied to miniCD4 beads. Analysis of miniCD4-
puriﬁed gp140SF162ΔV2 by SDS-PAGE (A: lane 1—ﬂowthrough after miniCD4 beads incubation; lane 2—pool of miniCD4 elutions). Size exclusion-HPLC proﬁle of miniCD4-
puriﬁed gp140SF162ΔV2 (B; panel 1—ﬂowthrough after miniCD4 beads incubation; panel 2—pool of miniCD4 elutions).
Fig. 6. Binding sensorgrams of miniCD4-puriﬁed gp140SF162ΔV2 to anti-gp120 mAbs.
The binding of miniCD4-puriﬁed gp140SF162ΔV2 on 48D (A) or X5 (B) antibody, in the
presence or not of 100 nM sCD4was analyzed by SPR. Binding sensorgrams of miniCD4-
puriﬁed gp140SF162ΔV2 diluted at 50 nM, 25 nM, 12.5 nM, 6.25 nM and 3.125 nM to
b12 (C) or 447-52D (D) mAbs.
244 G. Martin et al. / Virology 381 (2008) 241–250which possess a size of 300 kDa (6.5 ml). The fractions constituting
peak C were pooled and analyzed by SDS-PAGE (Fig. 1C). Silver
staining revealed a purity of gp120SF162 estimated at N90% by
densitometric scanning.
Binding of miniCD4-puriﬁed gp120SF162 to CCR5 receptor
The interaction of CD4 with gp120 allows the subsequent binding
of gp120 to a chemokine receptor through an important conforma-
tional change. In order to evaluate the activity of gp120SF162 puriﬁed
from miniCD4 afﬁnity chromatography, HIV envelope was pre-
incubated or not with soluble CD4 (sCD4) and then assessed for its
binding activity towards CCR5 chemokine receptor. Addition of sCD4
increased the binding of gp120SF162 puriﬁed by miniCD4 afﬁnity
chromatography to CCR5 receptor (Fig. 2, comparison of lane 1 and
lane 3), leading to a binding activity comparable to gp120 puriﬁed by
the reference method and associated with sCD4 (Fig. 2, lane 3
compared to lane 4).
Immunochemical characterization of miniCD4-puriﬁed gp120SF162
The structural integrity of gp120SF162 puriﬁed with the miniCD4
afﬁnity chromatography method was further analyzed by surface
immunoprobing with a panel of mAbs of deﬁned epitope speciﬁcities,
using Surface Plasmon Resonance (SPR) and capture ELISA. Upon
binding to sCD4, miniCD4-puriﬁed gp120SF162 underwent conforma-
tional changes as reﬂected by an increase binding of X5 and 48D CD4-
induced mAbs (CD4i Abs; Figs. 3A and B). MiniCD4-puriﬁed
gp120SF162 was also recognized by 447-52D anti-V3 loop and b12
anti-CD4 binding site mAbs (Figs. 3C and D).
TheminiCD4 afﬁnity chromatography was further compared to the
reference method. HIV gp120SF162 envelopes puriﬁed by the two
methodswere analyzed for their ability to bind a panel of well-deﬁned
mAbs. First, the concentration of envelopes was normalized through
ELISA assays using D7324 mAb (Fig. 4A). Then, gp120SF162 envelopes
puriﬁed by miniCD4 (named miniCD4) or by the reference method
(named multi) were assessed by using mAbs directed against CD4i
epitopes (X5, 48D and 17b), CD4 binding site (b12, F105), carbohydratemoieties (2G12) and V3 loop (447-52D). Despite the moderate degree
of purity of gp120SF162 puriﬁed in one step by miniCD4 (Fig. 1A), a
similar antibody-binding was observed for both gp120SF162 glyco-
proteins (Figs. 4B–H), suggesting that miniCD4 allows the separation
of HIV-1 envelope with intact epitopes.
Puriﬁcation of trimeric gp140 by miniCD4
MiniCD4 afﬁnity chromatography was further assessed for its
ability to capture gp140 trimer. 50 μg of gp140SF162ΔV2 puriﬁed by
themethod of referencewas diluted in 500 μl of PBS and incubated 1 h
at room temperature with an equal volume of miniCD4-beads. Then,
unbound and bound proteins from three independent experiments
were collected in a ﬁnal volume of 500 μl each. All the fractions were
further analyzed by spectrometry at 280 nm and by SPR (evaluation of
245G. Martin et al. / Virology 381 (2008) 241–250gp140 binding to 48D CD4i mAb). A percentage of 92.4±2.2% of gp140
captured by miniCD4 was measured by spectrometry, a comparable
yield of puriﬁcation was observed by SPR.
MiniCD4-puriﬁed gp140SF162ΔV2 was further analyzed by SDS-
PAGE, immunoblot and SEC (Fig. 5). MiniCD4 afﬁnity chromatography
allowed the elimination of contaminating proteins of lower molecular
mass (Fig. 5A, comparison of lane 1 and lane 2). MiniCD4 afﬁnity
chromatography appeared efﬁcient to reinforce the grade of purity of
pre-puriﬁed gp140, contaminant proteins of 50–70 kDa size should be
composed of bovine serum albumin, as previously shown for gp120
(Fig. 5A, line 1). Consistent with the yield of puriﬁcation described
above, a very low proportion of protein with gp140 molecular weight
was found in unbound fractions (Fig. 5A, lane 1). As expected,
miniCD4-puriﬁed gp140SF162ΔV2 migrated with an apparent mole-
cular mass of 140 kDa in reducing and denaturing conditions due to
the presence of gp41 ectodomain downstream gp120 core protein.
MiniCD4-puriﬁed gp140SF162ΔV2 was further analyzed over pre-
calibrated size exclusion-FPLC column (Bio-Sil SEC-250, Fig. 5B, panel
2). Based on the volume of elution of gp120 (7.4ml), gp140 (6.2ml) and
standards (670 kDa=5.52 ml; 158 kDa=7.12 ml; 44 kDa=7.79 ml;Fig. 7. Immunochemical characterization gp140SF162ΔV2 puriﬁed with the multi-step me
concentrations of gp140SF162ΔV2 puriﬁed with the multi-step method and submitted (ope
lectin (Concanavalin A) and incubated with a panel of mAbs i.e. 2G12 (A); b12 (B); F105 (C); 4
detected with peroxidase-labeled secondary antibodies. For X5, 48D and 17b binding gp140
shows the representative antibody-binding signal of 4 independent experiments. Leg
gp140ΔV2SF162 puriﬁed by miniCD4 afﬁnity chromatography.17 kDa=9.28 ml and 1.35 kDa=10.55 ml), the calculated molecular
masses of gp120SF162 and gp140SF162ΔV2 are 132.3 and 418.3 kDa,
respectively. The molecular mass of puriﬁed gp140SF162ΔV2 is the
expectedmolecularmass for a trimer (3×140kDa [monomer]=420 kDa
[trimer]), while gp120 one is slightly higher. Consistent with the
previous experiments, the SEC proﬁle of unbound fractions indicates
the presence of a low proportion of gp140 and contaminating proteins
of lower molecular weight (Fig. 5B, panel 1).
Immunochemical characterization of miniCD4-puriﬁed gp140SF162ΔV2
The structural integrity of gp140SF162ΔV2 puriﬁed with miniCD4
afﬁnitychromatographywas further evaluatedby SPRusing thepanel of
antibodies described for gp120SF162. MiniCD4-puriﬁed gp140 showed
an increased afﬁnity for both X5 and 48D CD4i mAbs in the presence of
sCD4 (Figs. 6A and B), and was recognized by b12 and 44752D mAbs
(Figs. 6C and D, respectively). Interestingly, gp140SF162ΔV2 koff is
reduced for all the antibodies tested compared to gp120SF162 one (see
Figs. 3 and 6), suggesting an increased avidity for gp140 consistent with
the trimeric conformation observed by SEC (Fig. 5B).thod and submitted (open square) or not (ﬁlled square) to miniCD4 capture. Various
n square) or not (ﬁlled square) to miniCD4 capture were pre-incubated on immobilized
8D (D); X5 (E); 17b (F); 447-52D (G); MN215 (H). Anti-gp120 mAbs binding was ﬁnally
SF162ΔV2 was pre-incubated in the presence of an equimolar concentration of sCD4. It
ends: “multi”: gp140ΔV2SF162 puriﬁed by the multi-step procedure, “miniCD4”:
Fig. 8. Puriﬁcation of gp120YU2 by theminiCD4method. Analysis of miniCD4-puriﬁed gp120YU2 by SDS-PAGE (A: lane 1, silver staining: pool of proteins eluted fromminiCD4-beads;
lane 2, immunoblot: identiﬁcation of gp120YU2 among the eluted protein by anti-gp120 D7324 mAb) and size exclusion-HPLC proﬁle of miniCD4-puriﬁed gp120YU2 (B).
Table 2




gp120CN54 (C) 3000 b100
gp120HxB2 (B) 1000 b100
gp120LAI (B) 600 b100
gp120SF162 (B) 1550 b100
gp120SF2 (B) 1400 b100
gp120W61D (B) 2000 b100
gp120YU2 (B) 2000 b100
gp140Br29 (F) 250 b100
gp140Bx08 (B) 450 b100
gp140ZM96 (C) 225 b100
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miniCD4 was ﬁnally compared to gp140ΔV2SF162 puriﬁed by the
reference method exclusively. Both gp140ΔV2SF162 concentrations
were normalized in ELISA by using 2G12 mAb (Fig. 7A). Afterwards,
the two trimers were analyzed for their ability to bindmAbs described
above (X5, 48D, 17b, b12, F105, 447-52D and MN215 mAbs). We found
that SF162 trimer antigenicity was perfectly preserved by theminiCD4
method of puriﬁcation (Figs. 7B–H). Taken together, these data
underline the usefulness of miniCD4 chromatographic method for
the puriﬁcation of functional and intact Env trimer.
Immunogenicity of miniCD4-puriﬁed envelopes
MiniCD4 afﬁnity chromatography was used to purify 1 mg of
gp120YU2 from 1 L of supernatant from cells over-expressing the
viral envelope (approximate concentration of gp120YU2 in cell
supernatant: 2 mg/L). In one step, gp120YU2 with a high grade of
purity was obtained, as shown by SDS-PAGE, immunoblot and SEC
analysis (Figs. 8A and B). Afterwards, three Wistar rats were
immunized with miniCD4-puriﬁed gp120YU2 or miniCD4 peptide
(used as control) using an intra-peritoneal boosting regimen. After
the second and the third intramuscular boosts with gp120YU2, an
important titer of antibody directed against the HIV envelope was
observed. Sera from the three rats immunized by either gp120YU2 or
miniCD4 were pooled and IgG were puriﬁed by afﬁnity chromato-
graphy using G protein (Amersham). Then, antibodies elicited by the
immunogens were evaluated for their ability to recognize a panel of
HIV-1 envelope monomers and trimers from diverse genetic sub-
types (clades B, C and F). Table 2 presents the dilutions of antibody
resulting in half-maximum binding to HIV-1 envelopes. MiniCD4-
puriﬁed gp120YU2 elicited a high titer of antibody directed against
envelope monomers from B and C clades. However, elicited
antibodies were less efﬁcient in recognizing gp140 trimers from B,
C and F clades; suggesting a certain proportion of antibody directed
against envelope domains which are inaccessible on oligomer
surface. This small scale immunogenicity study indicates that
miniCD4-puriﬁed gp120 is suitable for vaccine candidate preparation.
Furthermore, taken that miniCD4-puriﬁed envelopes possess an
intact CD4 binding site, this method of puriﬁcation may be
particularly appropriate for the preparation of antigen aiming to
induce antibodies directed against the CD4 binding site.Discussion
To address the many problems associated with the puriﬁcation of
HIV envelopes and particularly the separation of intact HIV envelope
trimer, we exploited the afﬁnity of miniCD4 for gp120 and gp140 to
develop an innovative method suitable for the puriﬁcation of highly
active and immunogenic HIV envelope.
HIV-1 envelope glycoprotein represents a major target for the
development of AIDS vaccines. Initial trials of HIV-1 Env-based
vaccines showed that soluble recombinant envelope glycoproteins
were well-tolerated and elicited neutralizing antibodies to the
homologous vaccine strain, but not to heterologous primary virus
isolates (Graham and Wright, 1995; Jeffs et al., 2004; Mascola et al.,
1996). Furthermore, these vaccines elicited sterilizing immunity
against homologous virus and a restricted panel of heterologous
virus in non-human primate models (Berman et al., 1990; Girard et al.,
1995, 1996; Stott et al., 1998). Those observations had led to numerous
envelope-based vaccines evaluated at both pre-clinical and clinical
stages (Graham, 2002; Graham and Mascola 2005; Gallo 2005; Girard
et al., 2006; Phogat and Wyatt, 2007). Nevertheless, the achievement
of these different vaccine candidates requires important quantities of
recombinant envelope monomer and/or trimer with intact epitopes
and functional CD4-binding sites. Therefore, it is necessary to have a
simple and reproducible method that lets the puriﬁcation of active
Env in good yields.
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gp120, anti-gp140 mAb afﬁnity chromatography. These methods may
require the conjunction of several steps of puriﬁcation such as ion
exchange and SEC and in most cases are speciﬁc to one HIV-1
envelope. To avoid a multi-step procedure and the use of anti-Env
antibody, we used a miniCD4 peptide presenting a high afﬁnity for
gp120 and gp140 (Martin et al., 2003; Stricher et al., 2005, 2008, Van
Herrewege et al., 2008; Vita et al., 1999). We showed that miniCD4
allowed the separation in one step of either gp120SF162 or gp120YU2
from cell supernatant. MiniCD4-puriﬁed gp120SF162 exhibited a high
afﬁnity for CD4, CCR5 and a panel of well-characterizedmAbs directed
against the CD4 binding site, CD4i epitopes and V3 loop. The afﬁnity of
miniCD4-puriﬁed gp120SF162 towards those ligands was comparable
to the one of gp120SF162 puriﬁed with a multi-step procedure
(Srivastava et al., 2002, 2003). Taken together, these data suggest that
the use of acidic conditions for the elution of gp120SF162 does not
affect the antigenic properties of the envelope glycoprotein. Finally,
we performed an immunogenicity study indicating that miniCD4
method of puriﬁcation is suitable for vaccine preparation, as miniCD4-
puriﬁed gp120YU2 elicited anti-envelope antibodies directed
against a broad range of genetic sub-types.
Taken the important need of envelope oligomers presenting intact
epitopes for vaccine application, miniCD4 afﬁnity chromatography
was also evaluated for its ability to capture Env trimer. In order to
achieve better immunogenicity with Env-based vaccines, attention
has focused on Env oligomer rather than monomer. The association of
envelope subunits in a trimeric conformation on HIV-1 surface shields
potential epitopes. Thus, antibodies induced by gp120 monomer react
more strongly to monomer as compared to oligomer (Burton and
Parren, 2000, Broder et al., 1994; Parren et al., 1998; VanCott et al.,
1995). Moreover, it has been well documented that gp120 monomers
are limited in their ability to neutralize primary isolates (Mascola et
al., 1996; Moore et al., 1995; VanCott et al., 1995; Wrin and Nunberg,
1994). Taken together, those observations had led to the engineering
of several gp140 trimers and their evaluation as vaccine candidate
(Barnett et al., 2008; Jeffs et al., 2004; Srivastava et al., 2002, 2003,
2008; Zhang et al., 2007). There are relatively few published studies
that describe the puriﬁcation of recombinant gp140 from eukaryotic
expression systems. The non-covalent association of the different
subunits forming gp140 trimer renders difﬁcult the puriﬁcation of
envelope oligomers with classical method such as lectin capture and
antibody-afﬁnity chromatography. Indeed, Jeffs and others had noted
the propensity of recombinant gp140/gp160 to form high molecular
weight aggregates, particularly when lectin afﬁnity chromatography is
used (Binley et al., 2000; Jeffs et al., 2004; Rhodes et al., 1994). In this
study, we found that miniCD4 was able to efﬁciently capture
gp140ΔV2SF162 trimer and that miniCD4-puriﬁed trimer presented
intact epitopes as shown by CD4 and mAbs binding. We also showed
that the grade of purity of pre-puriﬁed gp140ΔV2SF162 can be slightly
increased after the miniCD4 puriﬁcation step. Indeed, we showed that
miniCD4-eluted gp140 was separated from lower molecular mass
contaminants. Moreover, we did not observe aggregate formation
following the miniCD4 afﬁnity puriﬁcation. However, to address
precisely this point, miniCD4 puriﬁcation should be repeated on cell
supernatant of cell over-expressing gp140 rather than pre-puriﬁed
oligomer.
The advantages of the use of miniCD4 in a puriﬁcation method are
many fold. First, miniCD4 presents a high stability compared to
monoclonal antibodies. Indeed, miniCD4 is not affected by pH ranging
from 2 to 9, variation of temperature from 20 to 90 °C and presents an
important resistance to proteolytic degradation. Thus, miniCD4 beads
can be stored at 4 °C for a long period and reused several times
without signiﬁcant loss in their ability to capture Env. Second, because
of its well-deﬁned 3D structure and its reduced size (27 amino acids),
miniCD4 can be easily and rapidly produced by chemical synthesis and
labeled with afﬁnity tag such as biotin moiety. In addition, as miniCD4derives from a natural mini-protein its refolding is particularly easy
(seematerial andmethod part). Third, in a recent study, we and others
showed that CD4M48 and, more particularly, its derivative M48-U1
were able to neutralize a broad range of primary isolates (Van
Herrewege et al., 2008). Those data emphasized the high afﬁnity of
miniCD4 for oligomeric envelopes belonging to a broad spectrum of
HIV-1 primary strains. Thus, CD4M48 and M48-U1 could be
advantageously used to purify subtype C gp140, as well as a large
panel of Env from different clades. Fourth, another advantage inherent
to miniCD4-puriﬁcation is the selection of proteinwith accessible and
well-folded CD4-binding site. This region is recognized by a broadly
neutralizing antibody b12 mAb (Binley et al., 2004, Ruprecht et al.,
2003), which has been shown to present protective effects in non-
human primate challenged with SHIV (simian/human immunodeﬁ-
ciency virus) (Parren et al., 1995, 2001; Ruprecht et al., 2003; Veazey
et al., 2003). A recent study has shown that b12 mAb binding site
has considerable overlap with both CD4 and miniCD4 ones (Huang
et al., 2005; Zhou et al., 2007), suggesting that the selection of
envelopes with intact miniCD4 binding site might be particularly
attractive in vaccine preparation. Finally, the use of miniCD4 in a
puriﬁcation method represents a new example of applications of
mini-protein engineered by the transfer of active site onto small-
size scaffolds. Thus, biologically active mini-proteins may become
not only useful tools in biology and medical research, but also a
convenient step for protein puriﬁcation in academic and pharma-
ceutical researches.
Materials and methods
All Fmoc (ﬂuoren-9-ylmethoxycarbonyl)-protected amino acids
were from Nova Biochem (via VWR International, Fontenay-sous-Bois,
France). Fmoc-PAL-PEG-PS resin was from Applied Biosystems (via
Applera Corporation, Norwalk, CT, U.S.A.). All the other reagents and
solvents used in the synthesis and puriﬁcation of CD4M48 were from
Fulka (St Quentin Fallavier, France) or SDS (Solvants Documentation
Sytheses, Peypin, France). PBS and biotin and unspeciﬁed chemical
products were from Sigma Chemical Co. (St Louis, MO).
The matrix used to bind the biotinylated miniCD4 was a
Streptavidin Sepharose™ high performance from GE Healthcare Ltd
(Uppsala, Sweden). The labeled miniCD4 was grafted to the beads at
1 μM ﬁnal concentration.
Peptide synthesis
The miniCD4 CD4M48 was chemically synthesized on an Applied
Biosystems Synthesizer (model 433) by solid-phase method using
ﬂuorenylmethyloxycarbonyl-protected amino acids and N-hydroxy-
benzotriazole/dicyclohexylcarbodiimide coupling strategy (Drako-
poulou et al., 1996). The three disulﬁde bonds were formed with
the peptide dissolved at 0.1 mg/ml in 50 mM phosphate buffer (pH
7.8) in the presence of sequential addition of 5 mM reduced
glutathione followed by 0.5 mM oxidized glutathione. Synthetic
peptide was puriﬁed by reverse-phase HPLC, and its identity was
veriﬁed by amino-acid analysis and electrospray mass spectrometry.
The biotin moiety was speciﬁcally introduced at Lys11 by using N-α-
Fmoc-Nɛ-1-(ivDde-3-methylbutyl)-L-lysine (where ivDde is 4,4-
dimethyl-2,6-dioxocyclohex-1-ylidine) during peptide synthesis and
subsequent coupling of Fmoc-8-amino-3,6-dioxaoctanoic acid (linker
arm) and biotinamidohexanoic acid N-hydroxysuccinimide ester,
after ivDde was removed by four treatments of 3 min with 2%
hydrazine.
The CD4M48 amino-acid sequence is:
TpaNLHFCQLRC (K-Biot) SLGLLGRCAdPTFCACV
Lysine amino acid was derivatized with a Biotin (K-Biot) moiety;
dP was for (D)-proline and Tpa for thiopropionyl.
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The CHO cell line DG-44 was used for generation of stable cell lines
expressing either gp120SF162 (monomer) or gp140SF162ΔV2 (trimer
with a partial deletion in the second variable loop V2) (Srivastava et al.,
2002, 2003). The gene cassette used for the derivation of the stable cell
lines contains the protein-encoding region of the envelope protein
fused in frame to the human tissue plasminogen activator (t-PA) signal
sequence. The signal peptide of t-PA has been previously described to
increase the secretion of recombinant protein in the cell supernatant
(Chapman et al., 1991).
Concerning gp120YU2, the HIV-1 envelope glycoprotein was
produced in Spodotera frugiperda cells infected with Autographa
californica baculovirus AcSLP10 (Mechulam et al., 2005). As previously
described for the expression of HXB2, the natural signal peptide
sequence of gp120YU2was replaced by a new signal sequence isolated
from the ecdysteroid glycosyltransferase (EGT) gene of AcSLP10
baculovirus in order to increase the secretion of the glycoprotein in
cell supernatant (Misse et al., 1998).
MiniCD4 afﬁnity chromatography
Cell supernatant from cells over-expressing gp120SF162 was
concentrated 20-fold through a 100-kDa-pore-size membrane ﬁlter
and stored at −80 °C in the presence of 1 mM EDTA and 1 mM EGTA.
Prior the puriﬁcation process, the culture mediumwas ﬁltrated over a
0.45 μm ﬁlter, and protease inhibitors were added. Afterward, 500 μl of
culture medium was applied to 500 μl of miniCD4 beads (CD4M48
ﬁnal concentration being approximately 1 μM) and incubated with
gentle rocking overnight at 4 °C. After 5 washes with 500 μl of PBS,
proteins bound to the miniCD4 beads were recovered in 3 fractions of
250 μl of 25 mM citric acid pH 3.6 each. Finally, eluted fractions were
neutralized with 250 μl of 400 mM Citrate pH 6.8.
For scale-up growth, 1 L of cell supernatant from cell infected with
baculovirus producing gp120YU2 was divided in 200 ml fractions.
Each fraction was then incubated with 10 ml of miniCD4 beads over
night in rolling bottles at 4 °C. As it was the case for the small scale
analysis, the miniCD4 concentration in the mix was about 1 μM.
Finally, bound material was eluted in 2.5 ml of acidic solution and
neutralized with 2.5 ml of citrate solution as described above.
Multi-step method of puriﬁcation used as control
HIV-1 envelope glycoprotein puriﬁed with the miniCD4 afﬁnity
chromatography was compared to Env obtained via another method
of puriﬁcation (Srivastava et al., 2002; 2003). Brieﬂy, this multi-step
procedure of puriﬁcation is composed as followed, CHO cell super-
natant was loaded onto a DEAE (GE Healthcare Ltd) column
equilibrated with buffer (20 mM Tris, 100 mM NaCl, pH 8.0). Under
these conditions, gp120SF162 and gp140SF162ΔV2 did not bind to the
column, but contaminating proteins were retained on the column. The
DEAE ﬂowthrough was adjusted to 10 mM phosphate and pH 6.8 and
loaded on to a ceramic hydroxyapatite (CHAP, Biorad, Hercules, CA)
column equilibrated with buffer (10 mM Na2HPO4, 100 mM NaCl, pH
6.8). Envs were recovered in the ﬂowthrough, and the pH was
adjusted to 7.4 with 2 M Tris (pH 8.8) and loaded on to a protein-A-
agarose column to remove immunoglobulin contamination. The
protein-A-agarose ﬂowthrough was loaded onto a Galanthus Nivalis-
agarose (GNA) (Vector Laboratories, Burlingame, CA) column equili-
brated with 20 mM Tris–100 mM NaCl (pH 7.4). Bound Envs were
eluted with 500 mM methyl mannose pyranoside (Sigma Chemical
Co.) in equilibrated buffer. All the fractions containing the HIV-1
envelope glycoproteins were pooled and fractioned on Superose-6
and Superdex-200 (GE Healthcare Ltd) tandem columns equilibrated
with 10 mM Na-Citrate and 500 mM NaCl. Fractions containing Envs
were pooled, concentrated using a Stir cell (Millipore, Inc., Bedford,MA), and stored at −80 °C until used. HIV-1 envelope glycoproteins
puriﬁed with this approach were used through this study as control to
quantify gp120SF162 and gp120YU2 obtained with the miniCD4
afﬁnity chromatography. Envs obtained with this multi-step puriﬁca-
tion procedure were also termed ‘pre-puriﬁed Env’ and used to
characterize the miniCD4-based method of puriﬁcation.
Immunoblot analysis
Proteins were fractionated by SDS-PAGE and electro-blotted on
PVDF membrane. Transferred proteins were detected by binding of
anti-gp120 D7324 mAb (Aalto Bio Reagents, Dublin, Ireland) followed
by a horseradish peroxidase-conjugated anti-IgG sheep Ab. Immuno-
reactive protein bands were detected by autoradiography (Kodak,
Sigma) using an enhanced chemiluminescence assay (ECL, Amersham
Biosciences, Piscataway, NJ).
CD4 binding assay by ELISA
The capability of puriﬁed envelope protein to bind CD4, was
determined by using a sandwich ELISA assay (Stricher et al., 2005).
Brieﬂy, the 96-well plates (Maxisorb; Nunc, Rochester, NY) were coated
overnight at 4 °CwithD7324mAb (50ngperwell);wellswere saturated
with PBS/5% BSA buffer, washed three times, then different dilutions of
puriﬁed gp120SF162 or gp120YU2 were added, followed by an
incubationwith 62 pg of sCD4 (Progenic, Tarrytown, NY). For detection,
anti-CD4mAb L120.3 (Centralized Facilities for AIDS Reagents, National
Institute for Biological Standards and Control (NIBSC), South Mimms,
Potters Bar, Herts., U.K.) was added, followed by an incubation with
goat-antimouse peroxidase-conjugated antibody (Jackson Immunore-
search, West Grove, PA) and substrate (3,3′,5,5′-tetramethylbenzidine;
Sigma). The OD was measured at 450 nm and the concentration of
puriﬁed gp120 was determined by comparison with standard curves
derived from a known concentration of recombinant gp120SF162
puriﬁed with the multi-step method described above.
Immunological characterization of miniCD4-puriﬁed gp120
The binding of well-characterized HIV-Env speciﬁc mAbs was
performed by a capture ELISA. Typically, the 96-well plateswere coated
overnight at 4 °C with lectin (Concanavalin A, Sigma, 500 ng per well);
wells were saturated with PBS/5% BSA buffer, wash three times, and
different dilutions of puriﬁed gp120SF162 were added. The capture
proteins were revealed by incubation with 50 ng of anti-Env mAbs
(Centralized facilities for AIDS reagents, NIBSC) 1 h at room tempera-
ture. Several monoclonal antibodies were tested, directed against the
CD4-binding site (b12 and F105), CD4-induced epitopes (17b, X5 and
48D), V3 loop (MN215 and 447-52D), the carbohydrates moieties
(2G12) and the C-terminal part of gp120 (D7324). For CD4-induced
epitopes, gp120SF162 was pre-incubated with an equimolar concen-
tration of miniCD4 before the incubation with immobilized lectin. To
ﬁnish, plates were washed, and speciﬁcally bound antibodies were
detected using peroxidase-conjugated antibody as described earlier.
Size exclusion chromatography (SEC)
Puriﬁed gp120SF162, gp120YU2 and gp140SF162ΔV2 were
separated over pre-calibrated size exclusion-HPLC column (Bio-Sil
SEC-250, Biorad) by using ÄKTA puriﬁer apparatus (Amersham
Bioscience). Peak elutionwas monitored either at 280 nm or through
Tryptophan ﬂuorescence (λ excitation=280 nm and λ emission=
340 nm, values expressed in mV: mvolts). Tryptophan ﬂuorescence
was measured with a spectroﬂuorometer FL-detector L-2480 (VWR
International). Eluted proteins were calibrated by comparison with
the SEC proﬁle of molecular weight standards of 670, 158, 44, 17 and
1.35 kDa (Biorad).
249G. Martin et al. / Virology 381 (2008) 241–250Surface plasmon resonance (SPR) biosensor analysis
Experiments were conducted at 25 °C with 20 μl/min ﬂow rate in
HBS (10 mM HEPES-buffer saline, 3 mM EDTA, 0.05% Biacore
surfactant, pH 7.4) with a Biacore 3000 instrument (GE Healthcare,
Biacore AB, Uppsala, Sweden). All the antibodies tested were
immobilized at ∼1500 RU by the amine coupling kit (NHS/EDC)
provided by the manufacturer. We used the following panel of anti-
HIV-1 Env mAbs: D7324, X5, 48D, b12 and 447-52D. All the
sensorgrams were corrected by subtracting the signal from reference
ﬂow cell.
Cell surface CCR5 chemokine receptor binding assays
Adherent CHO-K1 cells expressing CCR5 (Samson et al., 1996) were
used to analyze envelope conformational change by ﬂow cytometry
FACS (Becton Dickinson, San Jose, CA). Typically, 100 ng of gp120SF162
or gp120YU2 (120 kDa) was pre-incubated or not with 36 ng of sCD4
(44 kDa) or 2.5 ng of miniCD4 (3 kDa) in 200 μl of PBS and then added
to 50 μl of HAMF12-FCS 10% medium containing 2×105 CCR5 cells.
After 1 h of incubation at room temperature, cells were washed 3
times with PBS/BSA 5% (pH 7.4). Envelope binding to CCR5 co-receptor
was further detected by a phycoerythrin-tagged antibody directed
against D7324 antibody.
Immunogenicity studies
Young Wistar rats were immunized by intra-peritoneal path (i.p.)
with 50 μg of miniCD4-puriﬁed gp120YU2 or 5 μg of miniCD4 CD4M48
emulsiﬁed in an equal volume of Alum adjuvant on day 0. Booster
inoculations were given i.p. on day 28, 56 and 84. 2 ml of serum was
collected at day 42, 70 and 98. Antibody titers were assayed using a
sandwich ELISA as follows: plates were coated with Concanavalin A
(500 ng per well) over night at 4 °C, saturated with PBS/BSA 5%,
pretreated 1 h with Env from different clades and then treated 1 h
with collected sera. Bound antibodies were revealed with goat-anti-
rat peroxidase-conjugated antibody.
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